Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer.

MLA

Ikarashi, Daiki, et al. “Pathological Complete Response to Neoadjuvant Chemotherapy May Improve Antitumor Immune Response via Reduction of Regulatory T Cells in Muscle-Invasive Bladder Cancer.” Scientific Reports, vol. 14, no. 1, Jan. 2024, p. 1442. EBSCOhost, https://doi.org/10.1038/s41598-024-51273-7.

APA

Ikarashi, D., Kitano, S., Tsuyukubo, T., Yamashita, M., Matsuura, T., Maekawa, S., Kato, R., Kato, Y., Kanehira, M., Takata, R., Sugai, T., & Obara, W. (2024). Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer. Scientific Reports, 14(1), 1442. https://doi.org/10.1038/s41598-024-51273-7

Chicago

Ikarashi, Daiki, Shigehisa Kitano, Takashi Tsuyukubo, Makiko Yamashita, Tomohiko Matsuura, Shigekatsu Maekawa, Renpei Kato, et al. 2024. “Pathological Complete Response to Neoadjuvant Chemotherapy May Improve Antitumor Immune Response via Reduction of Regulatory T Cells in Muscle-Invasive Bladder Cancer.” Scientific Reports 14 (1): 1442. doi:10.1038/s41598-024-51273-7.